Butzkueven, H. Et Al. 2007. Trial-defined disease progression in multiple sclerosis is a poor measure of permanent disability progression.. 59th Annual Meeting of the American-Academy-of-Neurology , (Massachusetts, United States Of America).

Butzkueven, H., Mechati, S., Hoffmann, M. W., Arruda, W., Boz, C., Bacile, E., ... Caride, A.(2007). Trial-defined disease progression in multiple sclerosis is a poor measure of permanent disability progression. . 59th Annual Meeting of the American-Academy-of-Neurology, Massachusetts, United States Of America

Butzkueven, Helmut Et Al. "Trial-defined disease progression in multiple sclerosis is a poor measure of permanent disability progression.," 59th Annual Meeting of the American-Academy-of-Neurology, Massachusetts, United States Of America, 2007

Butzkueven, Helmut Et Al. "Trial-defined disease progression in multiple sclerosis is a poor measure of permanent disability progression.." 59th Annual Meeting of the American-Academy-of-Neurology , Massachusetts, United States Of America, 2007

Butzkueven, H. Et Al. (2007) . "Trial-defined disease progression in multiple sclerosis is a poor measure of permanent disability progression.." 59th Annual Meeting of the American-Academy-of-Neurology , Massachusetts, United States Of America.

@conferencepaper{conferencepaper, author={Helmut Butzkueven Et Al. }, title={Trial-defined disease progression in multiple sclerosis is a poor measure of permanent disability progression.}, congress name={59th Annual Meeting of the American-Academy-of-Neurology}, city={Massachusetts}, country={United States Of America}, year={2007}}